OPPO Partners with Thales for World’s First 5G SA-Compatible eSIM
OPPO today announced the world’s first 5G SA-Compatible eSIM on its newly launched flagship 5G smartphone, the OPPO Find X3 Pro, developed in collaboration with the world’s leading eSIM connectivity management company, Thales. The 5G Standalone (SA) eSIM-based OPPO Find X3 Pro will provide users with the advanced 5G experience offered by 5G SA networks, as well as providing both users and mobile operators with the benefits of eSIM technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210526005008/en/
credit: Oppo Thales
Unlike traditional SIM cards which require to be physically inserted into devices, eSIM, or embedded SIM, is directly built into the device. Users can enjoy a trusted and smooth digital experience when selecting connectivity plans from their preferred mobile operators, from their smartphone. As such, the Thales eSIM also helps mobile operators to take up their digital transformation challenge. In addition to smartphones and wearables such as smartwatches, eSIMs also enjoys a widely growing adoption in Connected Vehicles and Industrial Internet of Things (IIOT).
As the mainstream 5G futureproof infrastructure, 5G SA (Standalone) networks, with lower latency, higher flexibility and a more comprehensive 5G experience, are being deployed by major mobile operators around the world. OPPO and Thales, being the first in the world to support 5G SA network on an eSIM-powered device, spearhead the development of 5G technology.
"As a leading global technology company, OPPO has been spurring the development of 5G technology since the very beginning. We are committed to providing innovative 5G experiences for users and we see eSIM as an exciting prospect in delivering these experiences,” said Xia Yang, Senior Director of Carrier Product, OPPO. “Through our technical collaboration with Thales, we have made the Find X3 Pro one of the first devices in the world to be equipped with 5G SA-Compatible eSIM. As 5G SA networks are being deployed around the world, the addition of 5G SA-Compatible eSIM brings more possibilities for Find X3 Pro users worldwide."
Thales is a world's leading provider in both hardware-based eSIM and eSIM connectivity management with more than 200 eSIM management platforms awarded by mobile operators, operator alliances, MVNOs, and OEMs across all continents. As OPPO's key eSIM solutions partner, Thales eSIM solutions have already been included in the OPPO Watch, OPPO’s first smartwatch with built-in cellular connectivity.
OPPO and Thales worked closely to integrate Thales’ innovative eSIM solution into the Find X3 Pro through eSIM server validation, device debugging, verification, function development, etc. OPPO and Thales have also worked with mobile operators to conduct network interoperability tests, in order to check that users can enjoy two simultaneous active lines (based on removable SIM and an eSIM) with their Find X3 Pro. This collaboration also demonstrates that 5G SA has been successfully implemented on an eSIM-compatible device for the first time.
"We are honored to continue our partnership with OPPO, for validating and commercializing the first 5G SA-Compatible eSIM on the OPPO Find X3 Pro,” said Jérôme Bendell, Vice President of Thales North Asia and CEO of Thales in China. “This is an important milestone in the development of eSIM technology. We believe that with the evolvement and widespread use of eSIM technology, it will further unlock the benefits of 5G to both operators and consumers. In particular, onboarding 5G SA eSIM helps maximize trust and resilience for mobile operators having deployed 5G core networks, and for their customers.”
Driven by user needs and experiences, OPPO began its research and development of eSIM technology in 2018 and has since launched a series of eSIM-Compatible smartphones and smartwatches. The OPPO Find X3 Pro equipped with 5G SA-Compatible eSIM not only demonstrates OPPO's strong technical expertise and insights into eSIM technology but also reflects OPPO’s investments in accelerating the rollout of 5G SA networks, allowing users to benefit from 5G experiences at the earliest opportunity.
OPPO is a leading global smart device brand. Since the launch of its first mobile phone - “Smiley Face” - in 2008, OPPO has been in relentless pursuit of the perfect synergy of aesthetic satisfaction and innovative technology. Today, OPPO provides a wide range of smart devices spearheaded by the Find X and Reno series. Beyond devices, OPPO provides its users with the ColorOS operating system and internet services like OPPO Cloud and OPPO+. OPPO operates in more than 40 countries and regions, with 6 Research Institutes and 5 R&D Centers worldwide, as well as an International Design Center in London. More than 40,000 of OPPO's employees are dedicated to creating a better life for customers around the world.
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For more details, please contact
OPPO International PR Team
Thales in China, Head of Government Affairs & Communications
+86 10 65875066
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 18:45:00 EEST | Press release
Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 10:01:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),
New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 10:00:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 12:53:00 EEST | Press release
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As
Slots Capital on useampien pelaajien ulottuvilla kuin koskaan aiemmin11.6.2021 12:23:00 EEST | Tiedote
Slots Capital on yksi maailman suosituimmista nettikasinoista. Nyt se on useampien pelaajien ulottuvilla kuin koskaan aiemmin, kun sivusto on ensimmäistä kertaa käynnistänyt toimintansa useissa uusissa maissa. Tämä tarkoittaa, että pelaajat Belgiassa, Romaniassa, Kreikassa, Tanskassa, Suomessa, Irlannissa, Latviassa ja Luxemburgissa voivat nyt nauttia Slots Capitalin huippuluokan nettikasinokokemuksesta. Jos rakastat kolikkopelien pelaamista, Slots Capital on todellakin sinua varten tarjoten yli 300 peliä isoilta pelinkehittäjiltä, kuten Rival, Saucify, Dragon ja Qora. Itse asiassa lisäsimme hiljattain kolikko- ja pöytäpeliaulaamme pelejä suosituilta studioilta, kuten Rival Gamingilta, Dragon Gamingilta, Saucify Gamingilta ja Qora Gamingilta. Lisäämme pelejä myös Arrow's Edgelta tulevina viikkoina, mutta sillä välin pelaajat voivat kokeilla peliaulamme uusimpia pelejä kuten: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wr
Slots Capital Available to More Players Than Ever Before11.6.2021 12:21:00 EEST | Press release
Slots Capital, one of the most popular online casinos in the world, in now available to more players than ever before after launching into several new countries for the very first time. This means players in Belgium, Romania, Greece, Denmark, Finland, Ireland, Latvia and Luxembourg can now enjoy the top-rated online casino experience offered at Slots Capital. If you love playing slots, then Slots Capital really is the place to be. In fact, we recently boosted our slots and table games lobby with titles from in-demand studios including Rival Gaming, Dragon Gaming, Saucify Gaming and Qora Gaming. We will also be adding slots from Arrow’s Edge in the coming weeks but in the meantime, players can try the latest titles to hit our lobby including: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wrath of Medusa Yeti Hunt i3D Slots Capital is not only known for being the number one destination for slots, players also love our daily
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 11:15:00 EEST | Press release
The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom